Collaboration focuses on developing and
implementing real-world research to drive patient access to cancer
medicines
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
biotechnology company that is developing and commercializing
innovative and affordable oncology medicines to improve treatment
outcomes and access for far more patients worldwide, today
announced a strategic agreement with Ontada®, a McKesson business
with leading provider technology and actionable real-world
research, education, and evidence in oncology, to improve U.S.
community oncology care through the development of real-world
evidence (RWE) data, tools, and insights to help increase access to
affordable, cutting-edge therapies.
The partnership will be led by Ontada and focus on accelerating
the development and implementation of RWE to improve community
education on the financial impact and value of oncolytics as well
as improve patient access to oncology medicines.
“BeiGene is excited to work with Ontada to advance our shared
vision of improving patient access, affordability, and value for
community oncology stakeholders and key partners working at the
intersection of clinical practice and real-world evidence,” said
Josh Neiman, Chief Commercial Officer, North America and Europe, at
BeiGene. “Working together, BeiGene and Ontada will generate novel
oncology insights through real-world data, tools, and technologies
that will facilitate the acceleration of precise decision-making in
support of community oncology practices whose ultimate mission is
to improve patient outcomes.”
As part of the collaboration, the companies will optimize the
use of RWE to communicate value across key stakeholders including
patients, providers, and payers; develop timely education on
emerging science and therapeutic differentiation; and collaborate
to advance use of RWE in healthcare and regulatory decision making
to increase timely and affordable patient access to life-saving
oncology therapies.
“BeiGene aims to bring 10 molecules per year to the clinic
starting in 2023 and, as this research advances, we’re delighted to
form this strategic partnership with McKesson, which shares the
same vision as BeiGene for improving the care of cancer patients,”
said Christiane Langer, M.D., Senior Vice President of Global
Medical Affairs, Ex-China, at BeiGene. “This collaboration will
leverage Ontada’s technology platform and deep understanding of the
experiences of patients treated in community oncology clinics to
help accelerate both the development of the BeiGene portfolio and
expand access to treatment options.”
“As a leader in real-world research, Ontada is uniquely
positioned to support complex research that uncovers deeper patient
insights and perspectives that advance cancer care,” said Susan
Shiff, Ph.D., president of Ontada. “We are excited to announce this
unique partnership with BeiGene and look forward to developing a
stronger understanding of how to better treat oncology patients
through the use of real-world data and evidence.”
About Ontada®
Ontada is an oncology technology and insights business dedicated
to transforming the fight against cancer. Part of McKesson
Corporation, Ontada was founded on the core belief that precise
insights – delivered exactly at the point of need – can save more
patients’ lives. We connect the full patient journey by combining
technologies used by The US Oncology Network and other community
oncology providers with real-world data and research relied on by
all top 15 global life sciences companies. Our work helps
accelerate innovation and power the future of cancer care. For more
information, visit ontada.com or follow @OntadaOncology.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader
dedicated to advancing health outcomes for patients everywhere. Our
teams partner with biopharma companies, care providers, pharmacies,
manufacturers, governments, and others to deliver insights,
products and services to help make quality care more accessible and
affordable. Learn more about how McKesson is impacting virtually
every aspect of healthcare at McKesson.com and read Our
Stories.
BeiGene Oncology
BeiGene is committed to advancing best- and first-in-class
clinical candidates internally or with like-minded partners to
develop impactful and affordable medicines for patients across the
globe. We have a growing R&D and medical affairs team of
approximately 2,900 colleagues dedicated to advancing more than 100
clinical trials that have involved more than 16,000 subjects. Our
expansive portfolio is directed predominantly by our internal
colleagues supporting clinical trials in more than 45 countries and
regions. Hematology-oncology and solid tumor targeted therapies and
immuno-oncology are key focus areas for the Company, with both
mono- and combination therapies prioritized in our research and
development. BeiGene currently has three approved medicines
discovered and developed in our own labs: BTK inhibitor BRUKINSA®
in the U.S., China, the European Union, Great Britain, Canada,
Australia, and additional international markets; and the
non-Fc-gamma receptor binding anti-PD-1 antibody, tislelizumab, as
well as the PARP inhibitor, pamiparib, in China.
BeiGene also partners with innovative companies who share our
goal of developing therapies to address global health needs. We
commercialize a range of oncology medicines in China licensed from
Amgen, Bristol Myers Squibb, EUSA Pharma and Bio-Thera. We also
plan to address greater areas of unmet need globally through our
other collaborations including with Mirati Therapeutics, Seagen,
and Zymeworks.
In January 2021, BeiGene and Novartis announced a collaboration
granting Novartis rights to co-develop, manufacture, and
commercialize BeiGene’s anti-PD1 antibody, tislelizumab, in North
America, Europe, and Japan. Building upon this productive
collaboration, BeiGene and Novartis announced an option,
collaboration, and license agreement in December 2021 for BeiGene’s
TIGIT inhibitor, ociperlimab, that is in Phase 3 development.
Novartis and BeiGene also entered into a strategic commercial
agreement through which BeiGene will promote five approved Novartis
Oncology products across designated regions of China.
About BeiGene
BeiGene is a global biotechnology company that is developing and
commercializing innovative and affordable oncology medicines to
improve treatment outcomes and access for far more patients
worldwide. With a broad portfolio, we are expediting development of
our diverse pipeline of novel therapeutics through our internal
capabilities and collaborations. We are committed to radically
improving access to medicines for far more patients who need them.
Our growing global team of more than 8,500 colleagues spans five
continents, with administrative offices in Beijing, China;
Cambridge, U.S.; and Basel, Switzerland. To learn more about
BeiGene, please visit www.beigene.com and follow us on Twitter at
@BeiGeneGlobal.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
the potential benefits of the strategic alliance and BeiGene’s
plans, commitments, aspirations and goals under the headings
“BeiGene Oncology” and “About BeiGene.” Actual results may differ
materially from those indicated in the forward-looking statements
as a result of various important factors, including BeiGene's
ability to demonstrate the efficacy and safety of its drug
candidates; the clinical results for its drug candidates, which may
not support further development or marketing approval; actions of
regulatory agencies, which may affect the initiation, timing and
progress of clinical trials and marketing approval; BeiGene's
ability to achieve commercial success for its marketed medicines
and drug candidates, if approved; BeiGene's ability to obtain and
maintain protection of intellectual property for its medicines and
technology; BeiGene's reliance on third parties to conduct drug
development, manufacturing and other services; BeiGene’s limited
experience in obtaining regulatory approvals and commercializing
pharmaceutical products and its ability to obtain additional
funding for operations and to complete the development of its drug
candidates and achieve and maintain profitability; and the impact
of the COVID-19 pandemic on BeiGene’s clinical development,
regulatory, commercial, manufacturing, and other operations, as
well as those risks more fully discussed in the section entitled
“Risk Factors” in BeiGene’s most recent quarterly report on Form
10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in BeiGene's subsequent filings with the
U.S. Securities and Exchange Commission. All information in this
press release is as of the date of this press release, and BeiGene
undertakes no duty to update such information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220815005080/en/
Investors Kevin Mannix +1 240-410-0129 ir@beigene.com
Media Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jun 2024 to Jul 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jul 2023 to Jul 2024